Designing Financial Milestones for Scientific Progress in MedTech

Let's consider a scenario where a medical device company is developing a minimally invasive surgical device expected to reach market in five years.

Source: Claude. Not intended to be precise or to be used for any purpose other than this article. Sources reviewed as reference: FDA, SVB MedTech Reports, EY MedTech Pulse, PitchBook, CMS DRG/APC data, AdvaMed

A company developing a minimally invasive device typically experiences value creation in discrete scientific and regulatory steps. Investors finance the company in stages because risk declines as the device moves from concept to clinical validation. The CFO’s role is to align capital deployment with these inflection points so that the company reaches each milestone with sufficient resources but without carrying excess burn before value is created.

The MedTech financial milestone framework therefore links three elements:

• technical progress,

• valuation expansion, and

• financing timing.

1. Key technical milestones investors care about

Investors in device development generally focus on milestones that reduce one of three risks: technical feasibility, regulatory feasibility, or clinical adoption risk.

Early milestones focus on engineering feasibility. These typically include proof-of-concept prototypes, benchtop validation, and confirmation that the device can perform its intended function reliably.

The next set of milestones relates to biological and safety validation. Preclinical testing in relevant animal models demonstrates safety, durability, and performance in physiologic conditions. At this stage investors evaluate whether the device can realistically proceed into human trials.

Regulatory preparation becomes the next inflection point. Key milestones include design freeze, verification and validation testing, completion of regulatory documentation, and submission readiness for FDA review.

Clinical milestones then dominate. First-in-human trials demonstrate safety and procedural feasibility. Pivotal clinical trials confirm effectiveness and provide the evidence required for regulatory clearance or approval.

Finally, early commercial adoption becomes the last milestone investors evaluate before large-scale growth. This includes initial hospital adoption, physician training success, and early procedural outcomes.

Each step meaningfully reduces uncertainty.

2. How each milestone affects company valuation

Valuation in MedTech is primarily driven by risk reduction rather than near-term revenue.

During the concept stage the company is valued largely on team credibility and intellectual property. Valuations are modest because technical feasibility is unproven.

When proof of concept is demonstrated, technical risk decreases and valuation typically increases materially. Investors now believe the engineering challenge is solvable.

Completion of strong preclinical data reduces biological and safety risk. At this stage investors can better estimate regulatory probability, which increases valuation further.

Regulatory submission readiness often produces another valuation step because development risk is largely known and timelines become more predictable.

The largest inflection point usually occurs after successful first-in-human trials. Human data confirms that the device works in clinical practice and dramatically increases investor confidence.

Final regulatory clearance and early commercial traction produce the highest valuation increases because revenue potential becomes credible rather than theoretical.

3. How funding rounds should align with milestones

Funding strategy should ensure that each round carries the company to the next major value inflection point.

Early seed or Series A capital typically funds engineering development through proof-of-concept and early preclinical work.

A subsequent Series B round is commonly raised after strong preclinical results. This round finances regulatory preparation, design verification, and readiness for clinical trials.

Another round may be raised prior to first-in-human trials if capital requirements are substantial. Investors at this stage expect to see clear regulatory alignment and strong technical validation.

Post-clinical financing rounds are usually raised after successful human data. These rounds fund pivotal trials, regulatory approval processes, and early commercialization preparation.

The objective is to raise capital immediately after a MedTech financial milestone when valuation has increased, rather than before the milestone when risk remains high.

4. Preventing overspending before major inflection points

Overspending typically occurs when companies scale infrastructure before uncertainty has been resolved.

The CFO prevents this by structuring budgets around milestone completion rather than time-based spending.

Engineering resources should focus only on activities necessary to achieve the next milestone. Hiring plans, equipment purchases, and external consulting engagements should be staged accordingly.

Large fixed costs such as manufacturing facilities or commercial organizations should be delayed until regulatory success becomes more certain.

Scenario planning is also essential. Development timelines frequently slip in medical device programs, so financial models should incorporate contingency assumptions. Maintaining capital buffers protects the company from needing emergency financing before reaching a milestone.

5. Financial planning that supports scientific teams without constraining innovation

Scientific teams require flexibility during development because engineering challenges often evolve unexpectedly. Financial discipline should therefore guide priorities without imposing rigid constraints.

The CFO can accomplish this by separating core milestone budgets from exploratory work. Core budgets fund the activities required to achieve regulatory and clinical milestones. Smaller discretionary budgets allow engineering teams to pursue alternative design approaches or technical improvements.

/

Regular cross-functional milestone reviews are also important. Engineering, clinical, regulatory, and finance teams should jointly assess progress and determine whether capital allocation should shift.

The role of finance is not to restrict experimentation but to ensure that experimentation remains aligned with value creation.